Modular Titratable Polypills for Personalized Medicine and Simplification of Complex Medication Regimens by Karavasili, Christina, Babaee, Sahab, Kutty, Shruti, Chu, Jacqueline N., Min, Seokkee, Fitzgerald, Nina, Morimoto, Joshua, Inverardi, Nicoletta, Traverso, Giovanni

“…Simplification of complex medication regimens in polypharmacy positively contributes to treatment adherence and cost‐effective improved health outcomes. …”
Get full text

The IDentif.AI-x pandemic readiness platform: rapid prioritization of optimized COVID-19 combination therapy regimens by Blasiak, Agata, Truong, Anh T. L., Remus, Alexandria, Hooi, Lissa, Seah, Shirley Gek Kheng, Wang, Peter, Chye, De Hoe, Lim, Angeline Pei Chiew, Ng, Kim Tien, Teo, Swee Teng, Tan, Yee-Joo, Allen, David Michael, Chai, Louis Yi Ann, Chng, Wee Joo, Lin, Raymond T. P., Lye, David C., Wong, John Eu-Li, Tan, Gladys Gek-Yen, Chan, Conrad En Zuo, Chow, Edward Kai-Hua, Ho, Dean

“…A starting pool of 12 candidate drugs developed in collaboration with a community of infectious disease clinicians was first narrowed down to a six-drug pool and then interrogated in 50 combination regimens at three dosing levels per drug, representing 729 possible combinations. …”
Get full text

Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses by Chauffour, Aurélie, Robert, Jérôme, Veziris, Nicolas, Aubry, Alexandra, Pethe, Kevin, Jarlier, Vincent

“…An intermittent oral regimen would facilitate treatment supervision. We first evaluated the bactericidal activity of newer antimicrobials against M. ulcerans using a BU animal model. …”
Get full text

A mixed methods study investigating factors affecting adherence to Plasmodium vivax malaria primaquine radical cure regimens among migrants along the Myanmar-Thailand border by Ansari, AT, Aung, KK, Win, HH, Beau, C, Nu, B, Soe, NL, Htoo, K, San, T, Wah, TG, Keereevijit, A, Phyo, AP, Chotivanich, K, White, NJ, Nosten, F, Hashmi, AH, Chu, CS

“…Understanding and facilitating adherence to primaquine radical cure regimens is necessary for malaria elimination. Methods: A convergent parallel mixed methods study was conducted to investigate the barriers to and facilitators for completing primaquine treatment of P. vivax infection among mobile migrant communities on the Myanmar-Thailand border. …”

Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial by De Botton, S, Risueño, A, Schuh, AC, Lowenberg, B, Kim, H-J, Vyas, P, Wei, AH, Stein, EM, Dohner, H, Fathi, AT, Dinardo, CD, Martin Regueira, P, Taningco, L, Bluemmert, I, Yu, X, See, WL, Hasan, M

The effect of early age feed restriction on subsequent response to high environmental temperatures in female broiler chickens by Zulkifli, I., Che Norma, M.T., Israf, D.A., Omar, A.R.

“…On Day 0, chicks were assigned to one of four feeding regimens; each regimen was applied to four cages of chicks. …”
Get full text

Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial by Silk, SE, Kalinga, WF, Salkeld, J, Mtaka, IM, Ahmed, S, Milando, F, Diouf, A, Bundi, CK, Balige, N, Hassan, O, Mkindi, CG, Rwezaula, S, Athumani, T, Mswata, S, Lilolime, NS, Simon, B, Msami, H, Mohamed, M, David, DM, Mohammed, L, Nyaulingo, G, Mwalimu, B, Juma, O, Mwamlima, TG, Sasamalo, IA, Mkumbange, RP, Kamage, JJ, Barrett, JR, King, LDW, Hou, MM, Pulido, D, Carnrot, C, Lawrie, AM, Cowan, RE, Nugent, FL, Roberts, R, Cho, J-S, Long, CA, Nielsen, CM, Miura, K, Draper, SJ, Olotu, AI, Minassian, AM

“…Children received either 10 μg RH5.1 at 0, 1, and 2 months (Children 10M) or 10 μg RH5.1 at 0, 1, and 6 months (delayed third dose regimen; Children 10D), and were recruited in parallel, followed by children who received the dose-escalation regimen (Children DFx) and children with higher malaria pre-exposure who also received the dose-escalation regimen (High Children DFx). …”

Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens by Barrett, JR, Silk, SE, Mkindi, CG, Kwiatkowska, KM, Hou, MM, Lias, AM, Kalinga, WF, Mtaka, IM, McHugh, K, Bardelli, M, Davies, H, King, LDW, Edwards, NJ, Chauhan, VS, Mukherjee, P, Rwezaula, S, Chitnis, CE, Olotu, AI, Minassian, AM, Draper, SJ, Nielsen, CM

“…Within protein/adjuvant groups, delayed boosting further improved B cell immunogenicity compared to a monthly boosting regimen. Consistent with this, delayed boosting also drove more durable anti-DBPRII serum IgG. …”

Optimising statistical methodologies for estimating antimalarial efficacy for uncomplicated Plasmodium falciparum malaria by Dahal, P

“…For dihydroartemisinin-piperaquine (DP) regimen, a study with 42 day follow-up was estimated to miss 47% [95% CI: 19 – 90%] of the treatment failures in those who were adequately dosed. …”

Novel viral vector vaccines for tropical infections by Rampling, T

“…Two studies evaluate the safety, efficacy and immunogenicity of a combination vaccination regimen containing the leading pre- erythrocytic <em>P. falciparum</em> malaria vaccine RTS,S/AS01B and the liver stage, viral vector heterologous prime-boost regimen of ChAd63 ME-TRAP and MVA ME-TRAP. …”

Quality of life and compliance with fluid restriction among hemodialysis patients in Hospital Universiti Sains Malaysia by Mohamad, Siti Aniza

“…In conclusion, patients’ knowledge and practice of treatment regimens has to be enhanced and improved so they will be knowledgeable and able to comply to treatment regimens thus increasing their quality of life.…”
Get full text

Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis by Chow, R, Basu, A, Kaur, J, Hui, D, Im, J, Prsic, E, Boldt, G, Lock, M, Eng, L, Ng, TL, Zimmermann, C, Scotte, F

“…However, there was no difference between cannabinoid and active treatment alternatives (most using dated single-agent regimens) for any outcomes. A recent phase II/III trial demonstrated superior efficacy of THC:CBD for secondary prevention of CINV when used as adjunctive therapy alongside modern antiemetic regimens, albeit mostly without olanzapine. …”

Advancing the chemotherapy of tuberculous meningitis: a consensus view by Wasserman, S, Donovan, J, Kestelyn, E, Watson, JA, Aarnoutse, RE, Barnacle, JR, Boulware, DR, Chow, FC, Cresswell, FV, Davis, AG, Dooley, KE, Figaji, AA, Gibb, DM, Huynh, J, Imran, D, Marais, S, Meya, DB, Misra, UK, Modi, M, Raberahona, M, Ganiem, AR, Rohlwink, UK, Ruslami, R, Seddon, JA, Skolimowska, KH, Solomons, RS, Stek, CJ, Thuong, NTT, van Crevel, R, Whitaker, C, Thwaites, GE, Wilkinson, RJ

“…Antimicrobial treatment is based on regimens used for pulmonary tuberculosis, which overlooks important differences between lung and brain drug distributions. …”

The impact of evolving SARS-CoV-2 mutations and variants on COVID-19 vaccines by McLean, Gary R., Kamil, Jeremy, Lee, Benhur, Moore, Penny, Schulz, Thomas F., Muik, Alexander, Sahin, Ugur, Tureci, Ozlem, Pather, Shanti

“…Although data on the effectiveness of the primary regimen against omicron (B.1.1.529) are limited, booster programs using mRNA vaccines have been shown to restore protection against infection and symptomatic disease (regardless of the vaccine used for the primary regimen) and maintain high effectiveness against hospitalization. …”
Get full text

Determining targets for antiretroviral drug concentrations: a causal framework illustrated with pediatric efavirenz data from the CHAPAS-3 trial by Schomaker, M, Denti, P, Bienczak, A, Burger, D, Díaz, I, Gibb, DM, Walker, AS, McIlleron, H

“…<p><strong>Background:&nbsp;</strong>Determining a therapeutic window for maintaining antiretroviral drug concentrations within an appropriate range is required for identifying effective dosing regimens. The limits of this window are typically calculated using predictive models. …”

Maximizing the performance of badminton athletes through core strength training: Unlocking their full potential using machine learning (ML) modeling by Ma, Shuzhen, Geok Soh, Kim, Japar, Salimah, Xu, Simao, Zhicheng, Guo

“…Incorporating core strength training into regular regimens can improve athletes' overall strength, endurance, balance, control, and prevent injuries. …”
Get full text

Treatment options to support the elimination of Hepatitis C: an open label, factorial randomised controlled trial by Cooke, G, Le Manh, H, Flower, B, McCabe, L, Vu Thu Kim, H, Vo Thi, T, Dang Trong, T, Nguyen Thanh, D, Le Thanh, P, Dao Bach, K, Nguyen Thi Chau, A, Pham Ngoc, T, Vu Thu Thu, H, Dang Thi, B, Nguyen Kim, T, Ansari, A, Le Ngoc, C, Vo Minh, Q, Nguyen Thi Ngoc, P, Le Thi, T, Nguyen Bao, T, Kestelyn, E, Kingsley, C, Van Doorn, R, Rahman, M, Pett, S, Thwaites, G, Barnes, E, Day, J, Nguyen Van Vinh, C, Walker, AS

“…No randomised trials have compared these regimens and high cure rates may be achievable with shorter durations of therapy.…”

Characterization of artemisinin resistance in plasmodium falciparum by Rocamora, Frances Maureen C.

“…In order to better understand the Artemisinin resistance phenotype, we developed Artemisinin-resistant parasite lines derived from two isogenic clones (6A and 11C) of the 3D7 strain of Plasmodium falciparum using a selection regimen that mimics how parasites interact with the drug in infected patients. …”
Get full text

Drug interaction between acetyltanshinone IIA and rapamycin in breast cancer cells by Wong, De Pin

“…Developing in vitro drug combination study is essential for the development of new and effective combination regimens. In this project, the objective is to investigate the synergistic potential between two anti breast cancer agent, rapamycin and acetyltanshinone IIA (ATA) in breast cancer cells. …”
Get full text

Using Sequenom to identify KRAS mutations in an Asian cohort of ovarian mucinous cancer by Tiong, Wen Ning

“…While there are distinct differences between mucinous epithelial ovarian cancer (mEOC) and the other subtypes of EOC, a standard treatment regimen is followed for all EOC histotypes. KRAS mutations have been observed to occur in relatively high frequencies of 50-60% in mEOC but not in other subtypes of EOC in at least three clinical studies. …”
Get full text